Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | DHODH | Q02127 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23367851 | 0.86 | NPC1 (0.50) | POLBALDH1A1ATMTSHRNPC1 | |
| SCHEMBL18117491 | 0.86 | ATM (0.53) | POLBALDH1A1ATMNPC1KDM4E | |
| SCHEMBL973238 | 0.83 | ATM (0.47) | ATMDHODH | |
| SCHEMBL28350646 | 0.83 | KMT2A (0.43) | POLBKDM4EDHODH | |
| SCHEMBL972255 | 0.83 | EGFR (0.48) | SMN1; SMN2DHODH | |
| SCHEMBL3685890 | 0.82 | HTT (0.43) | KDM4EDHODH | |
| SCHEMBL4930458 | 0.81 | RAB9A (0.50) | POLBALDH1A1ATMNAMPTNPC1 | |
| SCHEMBL18106786 | 0.81 | LMNA (0.48) | ALDH1A1NAMPTNPC1SMN1; SMN2MAPT | |
| SCHEMBL18117492 | 0.81 | ATM (0.48) | POLBALDH1A1ATMNPC1SMN1; SMN2 | |
| SCHEMBL22029381 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NAMPTNPC1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3677572-B1 | PRODUCTION METHOD FOR PYRAZOLE-4-CARBOXAMIDE DERIVATIVE | JAPAN FINECHEM COMPANY INC (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-3677572-A1 | PRODUCTION METHOD FOR PYRAZOLE-4-CARBOXAMIDE DERIVATIVE | Japan Finechem Company, Inc. (JP) | 2020-07-08 | — | — | EP | disclosed |
| US-20200181091-A1 | PRODUCTION METHOD FOR PYRAZOLE-4-CARBOXAMIDE DERIVATIVE | JAPAN FINECHEM COMPANY, INC. (JP) | 2020-06-11 | — | — | US | disclosed |
| CN-110891940-A | Process for preparing pyrazole-4-carboxamide derivatives | 日本凡凯姆股份有限公司 | 2020-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181091-A1 | PRODUCTION METHOD FOR PYRAZOLE-4-CARBOXAMIDE DERIVATIVE | AADAC, CYP3A4, ABAT | POLB 2215/4885ALDH1A1 412/4885ATM 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.